Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-03-23
2002-03-05
Jarvis, William R. A. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06353015
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a method of treatment or prophylaxis of neurological injury and neurodegenerative disorders in a mammal, particularly a human being. This method comprises the administration of a therapeutically effective amount of an N-acetylserotonin (NAS) derivative to the mammal.
2. Background
Nerve cell death (degeneration) can cause potentially devastating and irreversible effects for an individual and may occur e.g. as a result of stroke, heart attack or other brain or spinal chord ischemia or trauma. Additionally, neurodegenerative disorders-involve nerve cell death (degeneration) such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Down's Syndrome and Korsakoff's disease.
Therapies have been investigated to treat nerve cell degeneration and related disorders, e.g., by limiting the extent of nerve cell death that may otherwise occur to an individual. See, e.g., N. L. Reddy et al.,
J. Med. Chem
., 37:260-267 (1994); and WO 95/20950.
The compound MK-801 has exhibited good results in a variety of in vivo models of stroke. See B. Meldrum,
Cerebrovascular Brain Metab. Rev
., 2:27-57 (1990); D. Choi,
Cerebrovascular Brain Metab. Rev
., 2:105-147 (1990). See also Merck Index, monograph 3392, 11th ed., 1989. For example, MK-801 exhibits good activity in mouse audiogenic tests, a recognized model for evaluation of neuroprotective drugs. See, e.g., M. Tricklebank et al.,
European Journal of Pharmacology
, 167:127-135 (1989); T. Seyfried,
Federation Proceedings
, 38(10):2399-2404 (1979).
However, MK-801 also has shown toxicity and further clinical development of the compound is currently uncertain. See J. W. Olney et al.,
Science
, 244:1360-1362 (1989); W. Koek et al.,
J. Pharmacol. Exp. Ther
., 252:349-357 (1990); F. R. Sharp et al.,
Society for Neuroscience Abstr
., abstr. no. 482.3 (1992).
It thus would be highly desirable to have new neuroprotective agents, particularly agents to limit the extent or otherwise treat nerve cell death (degeneration) such as may occur with stroke, heart attack or brain or spinal cord trauma, or to treat neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, Down's Syndrome and Korsakoff's disease.
REFERENCES:
patent: 3642994 (1972-02-01), Anton-Tay
patent: 5284862 (1994-02-01), Bigge et al.
patent: 5491153 (1996-02-01), Salituro et al.
patent: 5700828 (1997-12-01), Federowicz et al.
patent: 6011054 (2000-01-01), Oxenkrug et al.
patent: 6063805 (2000-05-01), Oxenkrug et al.
patent: 6239162 (2001-05-01), Oxenkrug
Iacovitti et al, Chemical Abstracts on STN, abstract No. 127:257849, 1997.
Afanasiev Andrey Zakharovic
Bachurin Sergei O.
Oxenkrug Gregory F.
Requintina Pura J.
Jarvis William R. A.
Nixon & Peabody LLP
St. Elizabeth's Medical Center
LandOfFree
Method of treating neurodegenerative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating neurodegenerative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating neurodegenerative disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2818134